| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Prorenin is the inactive precursor of renin, a key enzyme for regulating blood pressure and electrolyte balance. Prorenin is known as an early marker of diabetic complications. This study aims to develop point-of-care testing (POCT) for prorenin. Through antibody screening, we identified the pairs of antibodies that simultaneously bind to two independent part of prorenin. With these antibodies, we established an enzyme-linked immunosorbent assay and POCT prototypes. Although the detection limit of prototypes is not enough to detect plasma prorenin, we shall create a POCT device for prorenin by solving the difficulties we found in this study.
|
